
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc is positioned favorably in the biotechnology sector with its innovative vaccine candidates, notably VAX-24 and VAX-31, demonstrating superior immune responses compared to existing competitors like Prevnar 20. The company has identified significant potential for global revenues exceeding $7-10 billion, supported by upcoming clinical data that may solidify its leadership in next-generation pneumococcal conjugate vaccines. As the company continues to generate encouraging results in both adult and pediatric studies, Vaxcyte reflects a compelling investment opportunity grounded in its strong clinical performance and market potential.
Bears say
The analysis of Vaxcyte Inc indicates a substantial negative outlook primarily due to several inherent risks in their clinical development process. Key concerns include potential delays in R&D, possible underperformance of vaccine efficacy or safety compared to expectations, and lower-than-anticipated commercial uptake, all of which could significantly impact their market position. Additionally, the ongoing uncertainty surrounding anti-vaccine sentiment and competition advancing more rapidly poses further threats to Vaxcyte's future revenue potential, especially if regulatory bodies do not endorse their vaccines as part of national vaccination guidelines.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares